Beyond the checklist: Assessing understanding for HIV vaccine trial participation in South Africa

Graham Lindegger, Cecilia Milford, Catherine Slack, Michael Quayle, Xolani Xaba, Eftyhia Vardas

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: Informed consent and understanding are essential ethical requirements for clinical trial participation. Traditional binary measures of understanding may be limited and not be the best measures of level of understanding. This study designed and compared 4 measures of understanding for potential participants being prepared for enrollment in South African HIV vaccine trials, using detailed operational scoring criteria. METHODS: Assessment of understanding of 7 key trial components was compared via self-report, checklist, vignettes, and narrative measures. Fifty-nine participants, including members of vaccine preparedness groups and 1 HIV vaccine trial, took part. RESULTS: There were significant differences across the measures for understanding of 5 components and for overall understanding. Highest scores were obtained on self-report and checklist measures, and lowest scores were obtained for vignettes and narrative descriptions. CONCLUSIONS: The findings suggest that levels of measured understanding are dependent on the tools used. Forced-choice measures like checklists tend to yield higher scores than open-ended measures like narratives or vignettes. Consideration should be given to complementing checklists and self-reports with open-ended measures, particularly for critical trial concepts, where the consequences of misunderstanding are potentially severe.

Original languageEnglish
Pages (from-to)560-566
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume43
Issue number5
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Keywords

  • Consent
  • Ethics
  • HIV vaccine trials
  • Understanding

Fingerprint

Dive into the research topics of 'Beyond the checklist: Assessing understanding for HIV vaccine trial participation in South Africa'. Together they form a unique fingerprint.

Cite this